Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 31, 2006

Avecia Tapped to Produce Illumigen’s Hepatitis C Drug

  • Avecia and Illumigen Biosciences entered into an agreement for the process development and manufacture of Illumigen's lead development product, IB657, for the treatment of Hepatitis C and other RNA viruses.

    Avecia will carry out development work to optimize the drug manufacturing process and conduct initial cGMP manufacture of IB657. This manufacturing agreement will provide Illumigen with IB657 in sufficient quantities to complete Phase Ia trials in Hepatitis C-infected patients.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »